Glutaminase 2 Negatively Regulates the PI3K/AKT Signaling and Shows Tumor Suppression Activity in Human Hepatocellular Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 May 7

PMID 24797434

Citations 58

Authors

Juan Liu

Cen Zhang

Meihua Lin

Wei Zhu

Yingjian Liang

Xuehui Hong

Yuhan Zhao

Ken H Young

Wenwei Hu

Zhaohui Feng

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53 and its signaling pathway play a critical role in tumor prevention. As a direct p53 target gene, the role of glutaminase 2 (GLS2) in tumorigenesis is unclear. In this study, we found that GLS2 expression is significantly decreased in majority of human hepatocellular carcinoma (HCC). Restoration of GLS2 expression in HCC cells inhibits the anchorage-independent growth of cells and reduces the growth of HCC xenograft tumors. Interestingly, we found that GLS2 negatively regulates the PI3K/AKT signaling, which is frequently activated in HCC. Blocking the PI3K/AKT signaling in HCC cells largely abolishes the inhibitory effect of GLS2 on the anchorage-independent cell growth and xenograft tumor growth. The GLS2 promoter is hypermethylated in majority of HCC samples. CpG methylation of GLS2 promoter inhibits GLS2 transcription, whereas reducing the methylation of GLS2 promoter induces GLS2 expression. Taken together, our results demonstrate that GLS2 plays an important role in tumor suppression in HCC, and the negative regulation of PI3K/AKT signaling contributes greatly to this function of GLS2. Furthermore, hypermethylation of GLS2 promoter is an important mechanism contributing to the decreased GLS2 expression in HCC.

Citing Articles

Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.

Guo Z, Ma J, Zhang J, Yan L, Zhou Y, Mao X Front Immunol. 2025; 16:1524801.

PMID: 39925801 PMC: 11802498. DOI: 10.3389/fimmu.2025.1524801.

GLS2 reduces the occurrence of epilepsy by affecting mitophagy function in mouse hippocampal neurons.

Gao Y, Ma L, Yuan J, Huang Y, Ban Y, Zhang P CNS Neurosci Ther. 2024; 30(10):e70036.

PMID: 39404053 PMC: 11474837. DOI: 10.1111/cns.70036.

Targeting amino acid-metabolizing enzymes for cancer immunotherapy.

Grobben Y Front Immunol. 2024; 15:1440269.

PMID: 39211039 PMC: 11359565. DOI: 10.3389/fimmu.2024.1440269.

CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas.

Ren Y, Bao X, Feng M, Xing B, Lian W, Yao Y Sci China Life Sci. 2024; 67(10):2169-2185.

PMID: 38987430 DOI: 10.1007/s11427-024-2591-7.

Glutaminase - A potential target for cancer treatment.

Anthony J, Varalakshmi S, Sekar A, Devarajan N, Janakiraman B, Peramaiyan R Biomedicine (Taipei). 2024; 14(2):29-37.

PMID: 38939098 PMC: 11204126. DOI: 10.37796/2211-8039.1445.

References

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

Licchesi J, Herman J . Methylation-specific PCR. Methods Mol Biol. 2008; 507:305-23. DOI: 10.1007/978-1-59745-522-0_22. View

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

Levine A, Hu W, Feng Z . The P53 pathway: what questions remain to be explored?. Cell Death Differ. 2006; 13(6):1027-36. DOI: 10.1038/sj.cdd.4401910. View

Li Y, Tollefsbol T . DNA methylation detection: bisulfite genomic sequencing analysis. Methods Mol Biol. 2011; 791:11-21. PMC: 3233226. DOI: 10.1007/978-1-61779-316-5_2. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Szeliga M, Obara-Michlewska M, Matyja E, Lazarczyk M, Lobo C, Hilgier W . Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia. 2008; 57(9):1014-23. DOI: 10.1002/glia.20825. View

Perez-Gomez C, Mates J, Gomez-Fabre P, Castillo-Olivares A, Alonso F, Marquez J . Genomic organization and transcriptional analysis of the human l-glutaminase gene. Biochem J. 2002; 370(Pt 3):771-84. PMC: 1223212. DOI: 10.1042/BJ20021445. View

10.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal J . The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008; 8(3):187-98. DOI: 10.2174/156800908784293659. View

11.

Mayo P, Hartshorne T, Li K, McMunn-Gibson C, Spencer K, Schnetz-Boutaud N . CNV analysis using TaqMan copy number assays. Curr Protoc Hum Genet. 2010; Chapter 2:Unit2.13. DOI: 10.1002/0471142905.hg0213s67. View

12.

Hu W, Chan C, Wu R, Zhang C, Sun Y, Song J . Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010; 38(5):689-99. PMC: 2900922. DOI: 10.1016/j.molcel.2010.05.027. View

13.

Suzuki S, Tanaka T, Poyurovsky M, Nagano H, Mayama T, Ohkubo S . Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010; 107(16):7461-6. PMC: 2867754. DOI: 10.1073/pnas.1002459107. View

14.

Michalowsky L, Jones P . Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance. Mol Cell Biol. 1987; 7(9):3076-83. PMC: 367939. DOI: 10.1128/mcb.7.9.3076-3083.1987. View

15.

Campos-Sandoval J, Lopez de la Oliva A, Lobo C, Segura J, Mates J, Alonso F . Expression of functional human glutaminase in baculovirus system: affinity purification, kinetic and molecular characterization. Int J Biochem Cell Biol. 2007; 39(4):765-73. DOI: 10.1016/j.biocel.2006.12.002. View

16.

Dell G, Charalambous M, Ward A . In vitro methylation of specific regions in recombinant DNA constructs by excision and religation. Methods Mol Biol. 2003; 181:251-8. DOI: 10.1385/1-59259-211-2:251. View

17.

Hu W, Feng Z, Teresky A, Levine A . p53 regulates maternal reproduction through LIF. Nature. 2007; 450(7170):721-4. DOI: 10.1038/nature05993. View

18.

Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R . Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4(1):1-7. DOI: 10.1016/s0960-9822(00)00002-6. View

19.

Baylin S, Esteller M, Rountree M, Bachman K, Schuebel K, Herman J . Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001; 10(7):687-92. DOI: 10.1093/hmg/10.7.687. View

20.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View